According to filings with the U.S. Securities and Exchange Commission, Tolerance Bio is raising up to $15,101,584.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Tolerance Bio
Tolerance Bio is a biopharmaceutical company dedicated to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance and a central organ of the immune system. The company is developing an allogeneic, off the shelf thymus induced pluripotent stem cell (iPSC)-based cell therapy platform, along with pharmacological thymus therapies, to treat immune-mediated diseases driven by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. Founded by Francisco Leon, MD, PhD, and based in Philadelphia, Pennsylvania, Tolerance Bio is pioneering a novel multi-platform approach to controlling immune tolerance by restoring, preserving, and manipulating thymic function as it naturally involutes with age. The company recently launched with an oversubscribed $17.2 million seed financing round led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners, and other biotechnology investors, underscoring strong investor confidence in its thymus-focused therapeutic strategy. With an accomplished team and an innovative focus on thymus-based therapies, Tolerance Bio positions itself at the forefront of efforts to address a broad range of serious immune-mediated diseases by targeting the fundamental mechanisms of immune tolerance.

To learn more, visit https://www.tolerancebio.com/
LinkedIn: https://www.linkedin.com/company/tolerance-bio/

Contact:
Francisco Leon, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.